We are thrilled to announce the filing of our broad-spectrum composition of matter patent application for our Kv1.3 project (VRG-K1). This significant milestone – given the advanced preclinical stage of our project – ensures lasting IP protection and brings us one step closer to making a positive impact on human health.

Our innovative Kv1.3 asset is designed to enable effective T cell inhibition, precisely targeting a specific subpopulation of T cells while sparing the broader immune system. The efficacy of our compound is backed by strong in vivo proof of concept studies. Moreover, this filing highlights the improved developability of our novel characterized compounds, marking a significant step forward in our journey to bring cutting-edge solutions to the market.

VRG-K1 will be utilized to treat chronic inflammatory diseases such as atopic dermatitis, opening up new possibilities for providing relief to millions of patients suffering from these debilitating conditions.

Stay tuned for more updates as we continue to push the boundaries of innovation!